NATTO: OPTIONS GRANTED
Oslo, Norway (8th February 2018) – Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 15th, 2017, and the option program related to defined operational objectives approved by the Board of Directors in 2017, the Board of Directors of NattoPharma has in board proceedings February 7th, 2018 granted a total of 560 350 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics.
The following persons on the executive management team have been granted options;
| Name | Granted Options | Optionsprior to grant | Optionsafter grant |
| Daniel H Rosenbaum | 184 300 | 163 000 | 347 300 |
| Kjetil Ramsøy | 88 600 | 74 000 | 162 600 |
Other employees and partners have been granted a total of 287 450 options.
The options have an exercise price equal the closing price on Oslo Axess on February 7th, 2018, which is equal to NOK 9,05.
The options granted are vested immediately and may be exercised up to and including March 31st, 2023.
* * *
For more information, please contact:
Kjetil Ramsøy,
CEO/CFO, NattoPharma
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 08:50 am CET on February 8th, 2018.